Cargando…
P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171572/ http://dx.doi.org/10.1097/01.HS9.0000936248.01150.e8 |
| _version_ | 1785039447854678016 |
|---|---|
| author | Searle, E. Quach, H. Wong, S. Costa, L. Hulin, C. Janowski, W. Berdeja, J. Anguille, S. Matous, J. Touzeau, C. Michallet, A. Husnik, M. Vishwamitra, D. Niu, Z. Larsen, J. Chen, L. Goldberg, J. Popat, R. Spencer, A. |
| author_facet | Searle, E. Quach, H. Wong, S. Costa, L. Hulin, C. Janowski, W. Berdeja, J. Anguille, S. Matous, J. Touzeau, C. Michallet, A. Husnik, M. Vishwamitra, D. Niu, Z. Larsen, J. Chen, L. Goldberg, J. Popat, R. Spencer, A. |
| author_sort | Searle, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171572 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101715722023-05-11 P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM) Searle, E. Quach, H. Wong, S. Costa, L. Hulin, C. Janowski, W. Berdeja, J. Anguille, S. Matous, J. Touzeau, C. Michallet, A. Husnik, M. Vishwamitra, D. Niu, Z. Larsen, J. Chen, L. Goldberg, J. Popat, R. Spencer, A. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171572/ http://dx.doi.org/10.1097/01.HS9.0000936248.01150.e8 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Searle, E. Quach, H. Wong, S. Costa, L. Hulin, C. Janowski, W. Berdeja, J. Anguille, S. Matous, J. Touzeau, C. Michallet, A. Husnik, M. Vishwamitra, D. Niu, Z. Larsen, J. Chen, L. Goldberg, J. Popat, R. Spencer, A. P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM) |
| title | P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM) |
| title_full | P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM) |
| title_fullStr | P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM) |
| title_full_unstemmed | P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM) |
| title_short | P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM) |
| title_sort | p30 single cohort results from majestec-2: teclistamab (tec) in combination with subcutaneous daratumumab (dara) and lenalidomide (len) in patients with multiple myeloma (mm) |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171572/ http://dx.doi.org/10.1097/01.HS9.0000936248.01150.e8 |
| work_keys_str_mv | AT searlee p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT quachh p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT wongs p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT costal p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT hulinc p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT janowskiw p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT berdejaj p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT anguilles p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT matousj p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT touzeauc p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT michalleta p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT husnikm p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT vishwamitrad p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT niuz p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT larsenj p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT chenl p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT goldbergj p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT popatr p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm AT spencera p30singlecohortresultsfrommajestec2teclistamabtecincombinationwithsubcutaneousdaratumumabdaraandlenalidomideleninpatientswithmultiplemyelomamm |